Skip to main content

ATLANTIS



ATLANTIS Trial Results

ATLANTIS trial main results: https://authors.elsevier.com/sd/article/S0140-6736(23)01523-4

ATLANTIS protocol paper: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06492-6

NIHR Alert May 2024: Irritable bowel syndrome: low dose antidepressant improves symptoms.

BMJ.com: Irritable bowel syndrome: low dose antidepressant improves symptoms

Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT https://www.journalslibrary.nihr.ac.uk/hta/BFCR7986#/abstract

ATLANTIS prizes awarded

British Society of Gastroenterology, 19 – 22 June 2023, Liverpool: Awarded “Best Oral Presentation in the neuro-gastroenterology section”
“Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial”

Royal College of General Practitioners Conference, 19 – 20 October 2023, Glasgow, UK – Awarded the “winning e-poster in the clinical category”
“Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial in Primary Care”

North American Primary Care Researcher Group (NPCRG), 30 Oct – 3 Nov 2023, San Francisco, USA – Awarded the “2023 NAPCRG Distinguished Paper Award”
“Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome in Primary Care: ATLANTIS: Randomised Controlled Trial”

Royal College of General Practitioners Conference, 3-4 October 2024, Liverpool –Awarded overall “RCGP Research paper of the year 2023” and winner of the “Clinical Research Award”
“Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial”
https://bjgplife.com/rcgp-research-paper-of-the-year-lessons-for-the-next-generation/

Top study in primary care from 2023 according to Canadian Family Physician, the journal of the College of Family Physicians of Canada:
Top studies of 2023 relevant to primary care | The College of Family Physicians of Canada (cfp.ca)

Ray Clouse Award for best research publication on functional gastrointestinal and motility disorders for 2024, awarded 18/5/2024
Ray Clouse Award – Rome Foundation (theromefoundation.org)

Downloadable Documents

STANDARD PRINT


Patients Results Summary (.pdf)
GP Results Summary (.pdf)
Rationale for Using Amitriptyline (.pdf)
Amitriptyline for IBS Dose Titration (.pdf)

LARGE PRINT


Patients Results Summary – Large Print (.pdf)
Rationale for Using Amitriptyline – Large Print (.pdf)
Amitriptyline for IBS Dose Titration – Large Print (.pdf)
Thank you from ATLANTIS
Thank you very much for your involvement in the ATLANTIS study.
We recruited 463 participants into the study and have analysed all the information we have collected. We are very grateful for your help with this study.

Thank you again for taking part. Research could not happen without people like you giving their valuable time.